Akovaz™ is indicated to treat clinically important hypotension in the setting of anesthesia. Approved in 2016, Akovaz™ is the only FDA-approved version of ephedrine sulfate.
Important Safety Information
INDICATIONS AND USAGE
AKOVAZ™ (ephedrine sulfate injection, USP) is an alpha- and beta- adrenergic agonist and a norepinephrine-releasing agent that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia.
WARNINGS AND PRECAUTIONS
- Pressor Effects with Concomitant Use with Oxytocic Drugs: Pressor effect of sympathomimetic pressor amines is potentiated
- Tachyphylaxis and Tolerance: Repeated administration of ephedrine may cause tachyphylaxis
Most common adverse reactions during treatment: nausea, vomiting, and tachycardia.
To report SUSPECTED ADVERSE REACTIONS, contact Avadel Legacy Pharmaceuticals, LLC at 1-877-622-2320 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.1116 AKO HCP ISI